RARE DISEASE
Fatal familial insomnia
Fatal familial insomnia
Fatal familial insomnia
Drug discovery
0
drugs
With orphan designations
Overview
Fatal Familial Insomnia (FFI) is a rare, autosomal dominant prion disease caused by a PRNP gene mutation (D178N with methionine at codon 129). It presents with progressive intractable insomnia, autonomic hyperactivity (tachycardia, hypertension, hyperhidrosis), and rapid neuropsychiatric decline, including ataxia, hallucinations, and dementia. Diagnosis relies on genetic testing, polysomnography (showing disrupted sleep architecture), and thalamic hypometabolism on PET imaging. No disease-modifying therapies exist; management is palliative, focusing on symptom relief. Prognosis is invariably fatal, with median survival of 7–36 months [1][2][6][10].
Categories: rare genetic diseases, rare neurological diseases
Research Papers
80 drug discovery papers about Fatal familial insomnia, with 1 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
80 drug discovery papers about Fatal familial insomnia, with 1 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
categories:
Small molecules
2026-02-12 | Modern view on prion diseases of the nervous system
Prion diseases (PDs) are rare neurodegenerative disorders caused by abnormal forms of the PrP protein, which can induce conformational changes in normal proteins and lead to progressive degeneration of nerve tissue. These diseases are characterized by a long incubation period and high mortality. The importance of studying PDs stems from the need to develop diagnostic and preventive methods, as well as the search for eff ective therapeutic agents. The article presents information on the mechanisms of damage to the nervous system, on the key forms of PDs (Creutzfeldt–Jakob disease, Gerstmann–Straussler–Scheinker syndrome, fatal familial insomnia, and others), presents modern diagnostic methods with an indication of their sensitivity and specifi city, and also considers promising areas of therapy (antisense oligonucleotides, antibodies, aggregation inhibitors, activation of autophagy, gene therapy).
2026-02-02 | Dreams as Sheaf Probes: The Transmission Gear Between Cache Identity and Context Identity
Four published instruments describe identity and consciousness at different temporal resolu- tions: the First-in Cache Identity (FCI) formalizes the self as a rolling buffer with anti-aliasing and monotone fictionalization at the micro-scale (seconds to minutes); the Sheaf-of-Contexts Identity (SCI) formalizes the self as a global section glued from context-local sections with ˇ Cech obstruction at the macro-scale (months to lifetime); the Individuals as Invariants frame- work provides the phenomenal field Φ and the CHIA composite-head architecture; and the Sleep-as-GLUE monograph (Monograph 98) establishes sleep as the canonical GLUE step in the Intercalation Lemma applied to the consciousness mezzanine. What has been missing is the transmission gear: the explicit mechanism that moves data from the FCI cache (RAM) to the SCI sheaf (map). We prove that sleep is that compiler. The wake–sleep cycle implements a discrete deployment schedule in which waking generates FCI local sections (the diffs) and sleep runs the GLUE operation that integrates them into the SCI global section (the merge). Dreams are the thermodynamic exhaust of this compilation—not hallucinations, not messages, but the visible residue of sheaf-compatibility audits conducted at blur β <β⋆ with guards deliberately relaxed. Dream content is Murphy-scheduled: it targets high-Ob/Lc overlaps where the identity sheaf is weakest. Dream phenomenology—vividness without epistemic worth, confidence without fidelity, discontinuity without detection—follows from FCI’s monotone fictionalization theorem operating at extreme parameters during the GLUE phase. We derive falsifiable predictions for dream content bias, vividness–blur coupling, post-learning replay specificity, and pathological modes (night terrors as cohomological write failures, insomnia as residual catastrophe, fatal familial insomnia as mezzanine evaporation, lucid dreaming as partial guard restoration). The synthesis completes the three-scale invariant theory of identity: FCI at the micro-scale, sleep at the meso-scale, SCI at the macro-scale, unified by the Intercalation Lemma and metered by the Murphy horiz
2026-01-25 | Genetic causes and modifiers of prion diseases.
Prion diseases are transmissible neurodegenerative diseases caused by misfolding of prion protein (PrP). All inherited prion diseases, including genetic Creutzfeldt-Jakob disease, Gerstmann-Sträussler-Scheinker disease, and fatal familial insomnia, are caused by pathogenic mutations in the prion protein gene (PRNP). The mutation partly dictates age at disease onset and clinical phenotype, presumably by its effects on the misfolding of PrP, but the clinical features can be highly variable even within the same pedigree. In sporadic prion diseases, genetic factors also play pivotal roles, as polymorphisms of PrP affect susceptibility, strain specificity, and disease progression. Additionally, emerging evidence highlights genetic modifiers outside PRNP that regulate disease susceptibility, implicating protein trafficking and lipid metabolism. Because individuals at genetic risk can be identified long before symptom onset, a distinctive opportunity exists for early or even presymptomatic therapeutic intervention. The unequivocal and well understood molecular target that is PrP, together with the development of diagnostic biomarkers, could create a favourable research setting for disease-modifying treatments.
2026-01-01 | Advancing prion diagnostics: full-length human E200K RT-QuIC substrate facilitates prion detection in tear fluid and improves sensitivity in cerebrospinal fluid
Abstract The real-time quaking-induced conversion (RT-QuIC) assay has revolutionized prion disease diagnosis by detecting amyloidogenic PrP conformers in different tissue types and body fluids. Recently, we achieved a breakthrough by detecting amyloidogenic PrP conformers in tear fluid (TF), a non-invasive biofluid, warranting further evaluation. We refined our RT-QuIC protocol to assess seeding conversion efficiency using various recombinant substrates, including full-length human (FL Hu), and mutant versions linked to genetic prion diseases, such as E200K and D178N, in both CSF and TF samples. Our study included patients with sporadic and familial prion diseases. FL Hu E200K showed the highest seeding efficiency in cerebrospinal fluid (CSF), with sensitivity increasing from 78 to 93% for symptomatic Creutzfeldt–Jakob disease (CJD) and from 19 to 75% for fatal familial insomnia (FFI) compared with the hamster-sheep substrate. For tear fluid, diagnostic sensitivity was 85% for sCJD and 64% for symptomatic genetic prion diseases, the assay was also able to detect amyloidogenic PrP in 57% of the healthy mutation carriers (HMC, persons at risk without symptoms). We validated the diagnostic accuracy of the TF RT-QuIC from our previous study (cohort 1) in a second independent study. Additionally, we confirmed that TF RT-QuIC requires FL Hu E200K substrates since hamster-sheep failed in detection of seeding activity in tears. Notably, only 1 out of 184 controls without prion disease tested positive. Studies comparing different disease stages (early vs. late) showed that later stages produced a stronger signal response. Our study demonstrates that the FL Hu E200K rec PrP substrate improves RT-QuIC sensitivity in CSF diagnostics and validates the reliable detection of seeding activity in TF in two cohorts as well as in HMC.
2025-07-04 | A review on current theories and potential therapies for prion diseases.
Prion diseases are neurodegenerative disorders that affect both humans and animals. They are commonly characterized by the absence of DNA and RNA and are distinguished from inherited or infectious forms. The cellular prion proteins (PrPC) misfold and accumulate into their pathogenic isoforms in these diseases. Disease conditions like Gerstmann-Straussler-Scheinker disease, Creutzfeldt-Jakob disease, and fatal familial insomnia are all related to prion proteins. The majority of the patients with prion disorders have a life expectancy of less than a year. An effective therapeutic approach for these prion diseases remains a formidable challenge. This review focuses on novel therapeutic approaches, such as antibody-based treatments that aim to stop normal proteins from changing into the harmful form of the prion protein (PrPSc). Additionally, the review discusses the potential of RNA interference, antisense oligonucleotides, anti-aggregation compounds, β-sheet breakers, and stem cell-based therapies in addressing prion diseases.
2026-02-12 | Modern view on prion diseases of the nervous system
Prion diseases (PDs) are rare neurodegenerative disorders caused by abnormal forms of the PrP protein, which can induce conformational changes in normal proteins and lead to progressive degeneration of nerve tissue. These diseases are characterized by a long incubation period and high mortality. The importance of studying PDs stems from the need to develop diagnostic and preventive methods, as well as the search for eff ective therapeutic agents. The article presents information on the mechanisms of damage to the nervous system, on the key forms of PDs (Creutzfeldt–Jakob disease, Gerstmann–Straussler–Scheinker syndrome, fatal familial insomnia, and others), presents modern diagnostic methods with an indication of their sensitivity and specifi city, and also considers promising areas of therapy (antisense oligonucleotides, antibodies, aggregation inhibitors, activation of autophagy, gene therapy).
2026-02-02 | Dreams as Sheaf Probes: The Transmission Gear Between Cache Identity and Context Identity
Four published instruments describe identity and consciousness at different temporal resolu- tions: the First-in Cache Identity (FCI) formalizes the self as a rolling buffer with anti-aliasing and monotone fictionalization at the micro-scale (seconds to minutes); the Sheaf-of-Contexts Identity (SCI) formalizes the self as a global section glued from context-local sections with ˇ Cech obstruction at the macro-scale (months to lifetime); the Individuals as Invariants frame- work provides the phenomenal field Φ and the CHIA composite-head architecture; and the Sleep-as-GLUE monograph (Monograph 98) establishes sleep as the canonical GLUE step in the Intercalation Lemma applied to the consciousness mezzanine. What has been missing is the transmission gear: the explicit mechanism that moves data from the FCI cache (RAM) to the SCI sheaf (map). We prove that sleep is that compiler. The wake–sleep cycle implements a discrete deployment schedule in which waking generates FCI local sections (the diffs) and sleep runs the GLUE operation that integrates them into the SCI global section (the merge). Dreams are the thermodynamic exhaust of this compilation—not hallucinations, not messages, but the visible residue of sheaf-compatibility audits conducted at blur β <β⋆ with guards deliberately relaxed. Dream content is Murphy-scheduled: it targets high-Ob/Lc overlaps where the identity sheaf is weakest. Dream phenomenology—vividness without epistemic worth, confidence without fidelity, discontinuity without detection—follows from FCI’s monotone fictionalization theorem operating at extreme parameters during the GLUE phase. We derive falsifiable predictions for dream content bias, vividness–blur coupling, post-learning replay specificity, and pathological modes (night terrors as cohomological write failures, insomnia as residual catastrophe, fatal familial insomnia as mezzanine evaporation, lucid dreaming as partial guard restoration). The synthesis completes the three-scale invariant theory of identity: FCI at the micro-scale, sleep at the meso-scale, SCI at the macro-scale, unified by the Intercalation Lemma and metered by the Murphy horiz
2026-01-25 | Genetic causes and modifiers of prion diseases.
Prion diseases are transmissible neurodegenerative diseases caused by misfolding of prion protein (PrP). All inherited prion diseases, including genetic Creutzfeldt-Jakob disease, Gerstmann-Sträussler-Scheinker disease, and fatal familial insomnia, are caused by pathogenic mutations in the prion protein gene (PRNP). The mutation partly dictates age at disease onset and clinical phenotype, presumably by its effects on the misfolding of PrP, but the clinical features can be highly variable even within the same pedigree. In sporadic prion diseases, genetic factors also play pivotal roles, as polymorphisms of PrP affect susceptibility, strain specificity, and disease progression. Additionally, emerging evidence highlights genetic modifiers outside PRNP that regulate disease susceptibility, implicating protein trafficking and lipid metabolism. Because individuals at genetic risk can be identified long before symptom onset, a distinctive opportunity exists for early or even presymptomatic therapeutic intervention. The unequivocal and well understood molecular target that is PrP, together with the development of diagnostic biomarkers, could create a favourable research setting for disease-modifying treatments.
2026-01-01 | Advancing prion diagnostics: full-length human E200K RT-QuIC substrate facilitates prion detection in tear fluid and improves sensitivity in cerebrospinal fluid
Abstract The real-time quaking-induced conversion (RT-QuIC) assay has revolutionized prion disease diagnosis by detecting amyloidogenic PrP conformers in different tissue types and body fluids. Recently, we achieved a breakthrough by detecting amyloidogenic PrP conformers in tear fluid (TF), a non-invasive biofluid, warranting further evaluation. We refined our RT-QuIC protocol to assess seeding conversion efficiency using various recombinant substrates, including full-length human (FL Hu), and mutant versions linked to genetic prion diseases, such as E200K and D178N, in both CSF and TF samples. Our study included patients with sporadic and familial prion diseases. FL Hu E200K showed the highest seeding efficiency in cerebrospinal fluid (CSF), with sensitivity increasing from 78 to 93% for symptomatic Creutzfeldt–Jakob disease (CJD) and from 19 to 75% for fatal familial insomnia (FFI) compared with the hamster-sheep substrate. For tear fluid, diagnostic sensitivity was 85% for sCJD and 64% for symptomatic genetic prion diseases, the assay was also able to detect amyloidogenic PrP in 57% of the healthy mutation carriers (HMC, persons at risk without symptoms). We validated the diagnostic accuracy of the TF RT-QuIC from our previous study (cohort 1) in a second independent study. Additionally, we confirmed that TF RT-QuIC requires FL Hu E200K substrates since hamster-sheep failed in detection of seeding activity in tears. Notably, only 1 out of 184 controls without prion disease tested positive. Studies comparing different disease stages (early vs. late) showed that later stages produced a stronger signal response. Our study demonstrates that the FL Hu E200K rec PrP substrate improves RT-QuIC sensitivity in CSF diagnostics and validates the reliable detection of seeding activity in TF in two cohorts as well as in HMC.
2025-07-04 | A review on current theories and potential therapies for prion diseases.
Prion diseases are neurodegenerative disorders that affect both humans and animals. They are commonly characterized by the absence of DNA and RNA and are distinguished from inherited or infectious forms. The cellular prion proteins (PrPC) misfold and accumulate into their pathogenic isoforms in these diseases. Disease conditions like Gerstmann-Straussler-Scheinker disease, Creutzfeldt-Jakob disease, and fatal familial insomnia are all related to prion proteins. The majority of the patients with prion disorders have a life expectancy of less than a year. An effective therapeutic approach for these prion diseases remains a formidable challenge. This review focuses on novel therapeutic approaches, such as antibody-based treatments that aim to stop normal proteins from changing into the harmful form of the prion protein (PrPSc). Additionally, the review discusses the potential of RNA interference, antisense oligonucleotides, anti-aggregation compounds, β-sheet breakers, and stem cell-based therapies in addressing prion diseases.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
0 orphan drug designations.
0 orphan drug designations.
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI’s forecasts to outperform average preclinical success rates. Whether you’re expanding your R&D pipeline, evaluating a partnership, or simply have a question — we’d love to hear from you.